Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research4

FiltersClear all

Status

Completed4
Active, not recruiting1
Terminated1

Study type

Interventional3
Observational1

Phase

Phase 23
Not reported1

Investigator

Jean W. Pape2
Marshall J. Glesby1
Nishant Prasad1

Department

Medicine4

Condition

COVID-1918
Leukemia, Myeloid, Acute16
Prostatic Neoplasms13
Neoplasms11
HIV Infections10

Intervention type

Drug3
Device1
Dietary supplement1

Sponsor type

Cooperative group2
Industry1
NIH1

Start date

to

Has results posted3

Completed×Tuberculosis×Clear all

Showing 1–4 of 4 studiesSort:

CompletedInterventional · Phase 2NCT01936831 ↗
The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive Tuberculosis

Show all 50

Show fewer

Intervention: Drug: Isoniazid · Dietary supplement: Vitamin B6
Dates: Aug 2014 – Sep 2021· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

Tuberculosis

CompletedInterventional · Phase 2NCT03819114 ↗

An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

Marshall J. GlesbyPI

Intervention: Drug: Levonorgestrel (LNG)
Dates: May 2019 – Nov 2020· Results posted
Sponsor: AIDS Clinical Trial Group

HIV InfectionsTuberculosis

CompletedInterventional · Phase 2NCT05007821 ↗

A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination With a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis

Intervention: Drug: Linezolid 600 mg · Drug: Linezolid 1200 mg (QD) · Drug: Linezolid 1200 mg (TIW) · Drug: Bedaquiline 200 mg · Drug: Bedaquiline 100 mg · Drug: Delamanid 300 mg · Drug: Clofazimine 300 mg · Drug: Clofazimine 100 mg
Dates: Sep 2022 – Mar 2025· Results posted
Sponsor: AIDS Clinical Trial Group

Tuberculosis, Multidrug-ResistantTuberculosisTuberculosis, Pulmonary

CompletedObservationalNCT05981495 ↗

Clinical Evaluation of the NanoDetect-TB Mycobacterium Tuberculosis Detection Kit for the Diagnosis of Tuberculosis Disease

Nishant PrasadPI

Intervention: Device: NanoDetect-TB
Dates: Aug 2023 – Dec 2024 (est.)
Sponsor: NanoPin Technologies, Inc.

Tuberculosis, PulmonaryTuberculosis, ExtrapulmonaryTuberculosis Active